HER2+/HR+ Breast Carcinoma Advanced Adjuvant with Neratinib

被引：0
|
作者：
Bischoff, Angelika
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / 04期
关键词：
CANCER EXTENET; DOUBLE-BLIND; THERAPY;
D O I：
10.1159/000507534
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：180 / 180
页数：1
相关论文
共 50 条
  • [21] Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2+ breast cancer
    Cortes-Funes, H.
    Mendiola, C.
    Manso, L.
    Ciruelos, E.
    BREAST CANCER RESEARCH, 2009, 11 : S8 - S8
  • [22] Randomized Phase II trial evaluating three anti-diarrhoeal prophylaxis strategies in patients with HER2+/HR+ early breast cancer treated with extended adjuvant neratinib (DIANER GEICAM/2018-06)
    Gonzalez-Santiago, S.
    Gil-Gil, M.
    Carrasco, E.
    Martinez-Janez, N.
    Adamo, B.
    Antolin, S.
    Alonso, J. L.
    Vethencourt, A.
    Martinez-Vila, C.
    Galve, E.
    Rojo, F.
    Caballero, R.
    Casas, M.
    Cortazar, E.
    McCulloch, L.
    Vedovato, J. C.
    Martin, M.
    BREAST, 2023, 68 : S17 - S17
  • [23] Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2-Breast Cancer
    Bottosso, Michele
    Miglietta, Federica
    Vernaci, Grazia Maria
    Giarratano, Tommaso
    Dieci, Maria Vittoria
    Guarneri, Valentina
    Griguolo, Gaia
    CLINICAL CANCER RESEARCH, 2024, 30 (14) : 2884 - 2894
  • [24] Prognostic Parameters of Palbociclib in HR+/HER2-Advanced Breast Cancer: A Narrative Review
    Wang, Wei
    Wu, Jiayi
    Chen, Keyu
    Wang, Xiaojia
    Shao, Xiying
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [25] Prognostic Parameters of Palbociclib in HR+/HER2-Advanced Breast Cancer: A Narrative Review
    Wang, Wei
    Wu, Jiayi
    Chen, Keyu
    Wang, Xiaojia
    Shao, Xiying
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [26] PATIENT REPORTED HEALTH UTILITY IN HR+/HER2-ADVANCED/METASTATIC BREAST CANCER
    Mitra, D.
    Wood, R.
    De Courcy, J.
    Iyer, S.
    VALUE IN HEALTH, 2016, 19 (07) : A749 - A749
  • [27] Abemaciclib for the treatment of HR+/HER2- breast cancer
    Exman, Pedro
    Tolaney, Sara M.
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2018, 3 (03): : 151 - 161
  • [28] Risks and benefits from CDK inhibitors for advanced HR+ Her 2-breast cancer
    Messina, C.
    Messina, M.
    Zanardi, E.
    ANNALS OF ONCOLOGY, 2017, 28 (12) : 3099 - 3100
  • [29] Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2-Breast Cancer
    Chang, Jenny C.
    O'Regan, Ruth
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 : S1 - S14
  • [30] Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2-Advanced Breast Cancer
    Stellato, Daniel
    Thabane, Marroon
    Eichten, Caitlin
    Delea, Thomas E.
    CURRENT ONCOLOGY, 2021, 28 (01) : 491 - 508
12345